1-3 of 3
Markus Freudenreich
Close
Sort by
Journal Articles

Immunotherapy of Acute MYELOID LEUKEMIA: ANTI-LEUKEMIC EFFECTS by Unprimed or Primed, Selected or Unselected Effector T-CELLS.

Helga Schmetzer, PhD, Prof, Friedhelm R Schuster, MD, Raymund Buhmann, MD, Markus Freudenreich, Georg Doessinger, Anja Liepert, Christine Grabrucker, Brigitte Steger, Susanne Reuther, Andreas Kremser, Julia Loibl, Dorothea Fischbacher, Christoph Schmid, MD, Tanja Kroell, Dirk Busch, MD, Prof, Arndt Borkhardt, MD, Prof, Hans-Jochem Kolb, MD, Prof
Journal: Blood
Blood (2009) 114 (22): 5122.
https://doi.org/10.1182/blood.V114.22.5122.5122
Published: 2009
Journal Articles

Leukemia-Derived DC for T-Cell Therapy against AML Progenitor Cells

Helga Schmetzer, Anja Liepert, Christine Grabrucker, Dorothea Fischbacher, Markus Freudenreich, Marion Merle, Roland Reibke, Friedhelm Schuster, Susanne Reuther, Andreas Kremser, Julia Loibl, Christoph Schmid, Tanja Kroell, Arndt Borkhardt, Hans-Jochem Kolb
Journal: Blood
Blood (2008) 112 (11): 5442.
https://doi.org/10.1182/blood.V112.11.5442.5442
Published: 2008
Journal Articles

Quality of Leukemia-Derived Dendritic Cells (DC) and T-Cells Are Predictive for the Specific Anti-Leukemic Potential of DC-Trained T-Cells.

Helga Schmetzer, Christine Grabrucker, Anja Liepert, Andreas Kremser, Julia Loibl, Markus Freudenreich, Reibke Roland, Raymund Buhmann, Ting Yang, Christoph Schmid, Tanja Kroell, MTA, Hans-Jochem Kolb
Journal: Blood
Blood (2007) 110 (11): 4883.
https://doi.org/10.1182/blood.V110.11.4883.4883
Published: 2007